ClinicalTrials.gg
Not yet recruitingNCT06836726EVOUpdated Sep 24, 2026

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

A Phase 2 interventional study of Evofosfamide in Castration Resistant Prostate Cancer, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Prostatic Neoplasms by University Health Network, Toronto — 22 open to participants now, 28 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.

Planned enrollment
48th of 85
35 · median 48
Started
2026
with 3 others
Phase 2
29 of 101
7 open now
Primary completion
2028-10
later than 16 of 27 live
Registered
95th of 101
by date

Among the 101 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 48th largest by planned enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2026, is one of 29 in phase 2, reaches primary completion later than 16 of the 27 other live ones, and was the 95th registered.

Prostatic Neoplasms

7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 101 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Prostatic Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs. In those progressing after second-line Docetaxel or deemed ineligible to it, the use of alternate ARSI remains the most common line of therapy in our Province, in keeping with recent international recommendations. After baseline molecular imaging (PSMA and fluorodeoxyglucose (FDG) PET/CT), prior to evofosfamide initiation, subjects will be encouraged to undergo biopsy of a dominant lesion: FDG-, PSMA-uptake and/or conventional imaging determined (in order, and according to feasibility). Subjects will then receive the alternate ARSI (i.e., different from the one received in first line) as per current standard practice and Provincial drug plan coverage. Additionally, subjects will receive combinatorial evofosfamide at a dose of 480 mg/m2 intravenously (IV) over 60 minutes on Days 1, 8 and 15 of every 28-day cycle. Therapy will continue until disease progression, unacceptable toxicity as a result of evofosfamide, or subject withdrawal. Assessments during evofosfamide treatment will include history, physical exam, and blood tests at each monthly visit to monitor for toxicity. Response and progression will be evaluated by whole-body PSMA PET/CT scan every 8 weeks (± 3 days) and determined using (PE)RECIST v1.1 criteria. PSA, NE markers (e.g., Serum CHGA, NSE), organ function tests (e.g., liver, kidney) and investigational liquid biopsy samples will be followed every cycle (monthly). FDG PET/CT will be performed at baseline, at 6-10 weeks from the date of signing the informed consent form (ICF), and upon progression, irrespective of treatment discontinuation or initiation of another therapy. Subjects will be followed for survival endpoints following completion of this study treatment until death.

Read the detailed description

Evofosfamide at a dose of 480 mg/m2 IV over 60 minutes on Days 1, 8 and 15 of every 28-day cycle. Additionally, subjects will receive standard-of-care castration (medical or surgical) plus ARSI. On days when both an ARSI and evofosfamide are administered, the ARSI should be administered at least 2 hours before or at least 2 hours after completion of the evofosfamide infusion. The preferred order of administration is evofosfamide administered first, with the ARSI administered at least 2 hours following the completion of evofosfamide infusion.

03

Conditions studied

  • Castration Resistant Prostate Cancer

Browse trials for

Keywords

  • CRPC
  • Castration Resistant Prostate Cancer
  • ARSIs
  • androgen receptor signal inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age;
  2. Ability to understand the purposes and risks of the trial and has signed a written ICF approved by the investigator's REB;
  3. CRPC stage M1 based on conventional imaging (CT and/or bone scan) or PSMA PET;
  4. Progression (i.e., PSA rise of 25% or more, and absolute increase of 2 ng/mL or more from the nadir) to ARSIs (Abi or Enza or Daro or Apa monotherapy) and subsequent docetaxel or deemed ineligible for it;
  5. Ongoing castration therapy (e.g., surgical or medical with LHRH agonists/antagonist), with baseline testosterone level \<50ng/dL;
  6. (ECOG) Performance status 0-2;
  7. In subjects with known significant pulmonary disease (severe chronic obstructive or other pulmonary disease with hypoxemia), measure oxygen saturation using pulse oximeter after a 2-minute walk. Subjects must have oxygen saturation ≥90% to be eligible for the trial.

Exclusion criteria

Exclusion Criteria:

  • 1. ANC \<1,000/mm3, and/or \<9.0 g/dL, and/or count \<100,000/mm3; independent of transfusion and/or growth factors 2. Liver dysfunction: total , serum glutamic oxaloacetic transaminase (; aspartate aminotransferase [AST]) and/or serum glutamic-pyruvic transaminase (SGPT; alanine aminotransferase [ALT]) >1.5 × upper normal limit (UNL); 3. Inadequate renal function: creatinine >1.5 × UNL, or \<40 mL/min; 4. Any Grade 3 or greater toxicity experienced during treatment with prior ARSI; 5. Severe, active co-morbidity defined as follows:

    1. Myocardial infarction within 6 months prior to date of enrollment.
    2. Current severe or unstable angina.
    3. Functional Classification III/IV. (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.)
    4. Severe chronic obstructive or other pulmonary disease with hypoxemia at rest (requires supplementary oxygen, symptoms due to hypoxemia).
    5. History of any condition that in the opinion of the investigator, would preclude participation in this study.

      6. Known liver based on conventional imaging (i.e., abdominal CT and/or MR).

      7. Known brain, or epidural metastases (unless treated, well controlled, and not requiring steroidal therapy for at least 3 months).

      8. Major surgery (other than diagnostic surgery), open , or significant traumatic injury, ≤28 days prior to the date of signing . Subject must have completely recovered from surgery.

      9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.

      10. Treatment of PCa with radiation therapy or surgery ≤28 days prior to the Cycle 1 Day 1.

      11. Prior therapy with a hypoxic cytotoxin. 12. -infected patients with detectable viral load and/or on effective anti-retroviral therapy (ART) with undetectable viral load for less than 6 months. Note: HIV testing is not required for eligibility for this protocol. Drug-drug interactions with ART occur via many mechanisms, with cytochrome P450 -mediated interactions being the most common. Patients who are using concurrent strong or moderate CYP3A4 inhibitors (e.g., ritonavir, cobicistat) or strong or moderate CYP3A4 inducers must be switched to an alternate effective ART regimen ≥4 weeks before study enrollment or should be excluded from the study if their regimen cannot be altered.

      13. Active infection with or (i.e., detectable viral load) with or without active treatment in patients with previously known infection. Note: Only Hepatitis B testing is required for eligibility for this protocol as per standard practice prior to systemic therapy.

      14. Subjects who have exhibited allergic reactions to a structural compound similar to evofosfamide or the drug product .

      15. Subjects who are taking medications that prolong and have a risk of Torsades de Pointes (see Appendix A).

      16. Subjects with a QTc interval calculated according to Fridericia formula (QTC = QT / RR1/3) of >450 msec based on screening (ECG).

      17. Subjects with a history of long QT syndrome. 18. Subjects taking a medication that is a moderate or strong inhibitor or inducer of CYP3A4within 14 days or 5 half-lives (whichever is longer) prior to signing of ICF. (see Appendix B).

      19. Subjects taking a medication that is a sensitive substrate or substrates with a narrow therapeutic index of CYP3A4, CYP2D6, or CYP2C9 (see Appendix C).

      20. Any other significant concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this trial.

      21. Unwillingness or inability to comply with the study protocol for any reason.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs

    After baseline molecular imaging (PSMA and fluorodeoxyglucose (FDG) PET/CT), prior to evofosfamide initiation, subjects will be encouraged to undergo biopsy of a dominant lesion: FDG-, PSMA-uptake and/or conventional imaging determined (in order, and according to feasibility). Subjects will then receive the alternate ARSI (i.e., different from the one received in first line) as per current standard practice and Provincial drug plan coverage. Additionally, subjects will receive combinatorial evofosfamide at a dose of 480 mg/m2 intravenously (IV) over 60 minutes on Days 1, 8 and 15 of every 28-day cycle. Therapy will continue until disease progression, unacceptable toxicity as a result of evofosfamide, or subject withdrawal. Assessments during evofosfamide treatment will include history, physical exam, and blood tests at each monthly visit to monitor for toxicity. Subjects will be followed for survival endpoints following completion of this study treatment until death.

    Drug: Evofosfamide

Interventions

  • This study is evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.

06

What researchers measure

Primary outcomes

  1. Preliminary clinical efficacy measures of evofosfamide in subjects with CRPC progressing to first-line ARSIs +/- docetaxel

    Preliminary clinical efficacy measures of evofosfamide in subjects with CRPC (Castrate Resistant Prostate Cancer) progressing to first-line ARSIs (Androgen Receptor Signaling Inhibitor) +/- docetaxel will be determined. This is measured by the biochemical response rate (if the PSA (tumor marker) declined ≥50% compared to baseline). Sample(s) may be drawn with serum biochemistry sample(s).

    Time frame: Every 8 weeks (± 3 days) until death

Secondary outcomes

  1. Radiological (morphological and molecular) response rates

    Radiologic response rates (morphologic and molecular) measured using (PE)RECIST (Response evaluation criteria in solid tumors) criteria v1.1 on prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/ computerized tomography (CT).

    Time frame: Every 8 weeks (± 3 days) until death

  2. Professional free survival (PFS)

    PFS (progression free survival) from time of first evofosfamide treatment until biochemical \[increase in PSA (tumor marker) \>25% or an absolute increase of \>2 ng/mL over baseline or nadir\].

    Time frame: Every 8 weeks (± 3 days) until death

  3. Response rate and PFS (progression free survival) to subsequent therapies (PFS2)

    Radiological or clinical progression; occurrence rate and time-to-event of NEPC phenotype based on histological (e.g., small cell NEPC or adenocarcinoma with \>50% staining to CHGA and/or SYP and/or NSE), clinical (e.g., development of visceral metastases without biochemical progression) or biochemical (e.g., serum CHGA level \>5× and/or NSE \>2× UNL); response rate and PFS2.

    Time frame: Every 8 weeks (± 3 days) until death

  4. OS (overall survival)

    OS (overall survival) as time from first treatment until death.

    Time frame: Every 8 weeks (± 3 days) until death

  5. Changes in tumor biopsies

    Toxicity rates graded by CTCAE v5.0 (Common Terminology Criteria for Adverse Events).

    Time frame: Every 8 weeks (± 3 days) until death

  6. Circulating cfDNA markers in response to therapy

    Circulating cfDNA markers will be determined in response to therapy via molecular analyses on pre- and during-treatment tissue and/or liquid biopsies.

    Time frame: Every 8 weeks (± 3 days) until death

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's planned 24 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 20, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2030
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06836726
Collaborators
ImmunoGenesis
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Sep 24, 2026

Study contacts

Alejandro Berlin, MD
Contact
Alejandro.Berlin@uhn.ca
416-946-4501 ext. 5813

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion